Compare Mesoblast Limited (MESO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Paychex, Inc. — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Paychex, Inc. trades at $103.98 (market cap $37.19B). The key difference: Paychex, Inc. is far larger — about 21.3× Mesoblast Limited's market cap, and Paychex, Inc. pays a 4.56% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Paychex, Inc. for 56 Days on average.
| MESO | PAYX | |
|---|---|---|
Market Cap | $1.75B | $37.19B |
Volume | 239,027 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $20.96 | $128.59 |
52-Week Low | $13.19 | $85.57 |
Typical Hold Time | 15 Days | 56 Days |
Enterprise Value | $1.83B | $40.87B |
Dividend Yield | — | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Paychex (PAYX) trades at $103.98, up 2.39% with a bullish technical signal despite mixed indicators. The company demonstrates strong fundamentals with consistent earnings beats, 27.35% net margins, and robust profitability metrics. Recent news highlights investor concerns about dividend sustainability despite solid Q1 2027 results showing 6% revenue growth and double-digit earnings increases driven by PEO and insurance segments.
Outlook remains cautiously optimistic with a $111 consensus price target offering 6.8% upside. Key risks include labor market sensitivity and competitive pressures, while opportunities lie in AI integration and PEO growth. The stock presents a balanced risk-reward profile with dividend stability supporting investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
